ATNM
Actinium Pharmaceuticals, Inc.
Key Financials
Operating Income
$-36247000
↑ 13.9%
Revenue
$90000
↑ 11.1%
EPS (Diluted)
$-1.09
↑ 14.2%
Net Income
$-33887000
↑ 11.4%
Total Assets
$51.8M
↓ 32.7%
Shareholders' Equity
$7.8M
↓ 76.1%
Total Liabilities
$43.9M
↓ 0.5%
Cash & Equivalents
$48.0M
↓ 34.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/18/2026 | View on SEC |
| 8-K | 5/29/2026 | View on SEC |
| 10-Q | 5/8/2026 | View on SEC |
| 10-K | 3/30/2026 | View on SEC |
| 8-K/A | 3/26/2026 | View on SEC |
| 8-K | 2/13/2026 | View on SEC |
| 8-K | 11/26/2025 | View on SEC |
| 10-Q | 11/14/2025 | View on SEC |
| ARS | 11/5/2025 | View on SEC |
| DEF 14A | 11/5/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ATNM |
| Company Name | Actinium Pharmaceuticals, Inc. |
| CIK | 1388320 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (646) 677-3870 |